Evolving strategies in the management of aspergillosis.
Aspergillus spp. remain the most common causes of invasive mould infections among patients with hematologic malignancies and recipients of solid-organ and hematopoietic stem-cell transplants. Despite advances in prevention and treatment, invasive aspergillosis continues to be a deadly disease. This paper reviews current approaches to treatment of aspergillosis in adults, including surgical and immune-based strategies, and developments in prophylaxis for aspergillosis in high-risk patient populations.
Magill
Shelley S
SS
Centers for Disease Control and Prevention, Mycotic Diseases Branch, Division of Foodborne, Bacterial and Mycotic Diseases, 1600 Clifton Road, Mailstop C-09, Atlanta, GA 30333, USA. Smagill@cdc.gov
Chiller
Tom M
TM
Warnock
David W
DW
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy*; D019468:Disease Management; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends
D000935:Antifungal Agents